{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T12:59:22Z","timestamp":1780750762558,"version":"3.54.1"},"publisher-location":"New York, NY","reference-count":86,"publisher":"Springer US","isbn-type":[{"value":"9781071647295","type":"print"},{"value":"9781071647301","type":"electronic"}],"license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025]]},"DOI":"10.1007\/978-1-0716-4730-1_5","type":"book-chapter","created":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T13:01:43Z","timestamp":1753707703000},"page":"97-108","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Tips to Design Effective Splice-Switching Antisense Oligonucleotides for Exon Skipping and Exon Inclusion"],"prefix":"10.1007","author":[{"given":"Rika","family":"Maruyama","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshifumi","family":"Yokota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,29]]},"reference":[{"issue":"3","key":"5_CR1","doi-asserted-by":"publisher","first-page":"144","DOI":"10.3390\/jpm3030144","volume":"3","author":"JJ Lee","year":"2013","unstructured":"Lee JJ, Yokota T (2013) Antisense therapy in neurology. Journal of personalized medicine 3(3):144\u2013176. https:\/\/doi.org\/10.3390\/jpm3030144","journal-title":"Journal of personalized medicine"},{"issue":"13","key":"5_CR2","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.4155\/fmc.15.116","volume":"7","author":"A Guncay","year":"2015","unstructured":"Guncay A, Yokota T (2015) Antisense oligonucleotide drugs for Duchenne muscular dystrophy: how far have we come and what does the future hold? Future Med Chem 7(13):1631\u20131635. https:\/\/doi.org\/10.4155\/fmc.15.116","journal-title":"Future Med Chem"},{"issue":"6","key":"5_CR3","doi-asserted-by":"publisher","first-page":"3652","DOI":"10.4049\/jimmunol.176.6.3652","volume":"176","author":"TA Vickers","year":"2006","unstructured":"Vickers TA, Zhang H, Graham MJ et al (2006) Modification of MyD88 mRNA splicing and inhibition of IL-1beta signaling in cell culture and in mice with a 2\u2032-O-methoxyethyl-modified oligonucleotide. J Immunol 176(6):3652\u20133661","journal-title":"J Immunol"},{"issue":"1507","key":"5_CR4","first-page":"145","volume":"58","author":"NIH","year":"2016","unstructured":"NIH (2016) Eteplirsen (Exondys 51) for duchenne muscular dystrophy. Med Lett Drugs Ther 58(1507):145\u2013146","journal-title":"Med Lett Drugs Ther"},{"key":"5_CR5","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/978-1-4939-7374-3_10","volume":"1687","author":"T Shimo","year":"2018","unstructured":"Shimo T, Maruyama R, Yokota T (2018) Designing effective antisense oligonucleotides for exon skipping. Methods Mol Biol 1687:143\u2013155. https:\/\/doi.org\/10.1007\/978-1-4939-7374-3_10","journal-title":"Methods Mol Biol"},{"issue":"7","key":"5_CR6","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1038\/jhg.2016.28","volume":"61","author":"A Nakamura","year":"2016","unstructured":"Nakamura A, Fueki N, Shiba N et al (2016) Deletion of exons 3-9 encompassing a mutational hot spot in the DMD gene presents an asymptomatic phenotype, indicating a target region for multiexon skipping therapy. J Hum Genet 61(7):663\u2013667. https:\/\/doi.org\/10.1038\/jhg.2016.28","journal-title":"J Hum Genet"},{"issue":"4","key":"5_CR7","first-page":"498","volume":"45","author":"M Koenig","year":"1989","unstructured":"Koenig M, Beggs AH, Moyer M et al (1989) The molecular basis for Duchenne versus Becker muscular dystrophy: correlation of severity with type of deletion. Am J Hum Genet 45(4):498\u2013506","journal-title":"Am J Hum Genet"},{"key":"5_CR8","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1038\/jhg.2016.152","volume":"62","author":"A Nakamura","year":"2016","unstructured":"Nakamura A, Shiba N, Miyazaki D et al (2016) Comparison of the phenotypes of patients harboring in-frame deletions starting at exon 45 in the Duchenne muscular dystrophy gene indicates potential for the development of exon skipping therapy. J Hum Genet 62:459. https:\/\/doi.org\/10.1038\/jhg.2016.152","journal-title":"J Hum Genet"},{"issue":"16","key":"5_CR9","doi-asserted-by":"publisher","first-page":"4213","DOI":"10.1073\/pnas.1613203114","volume":"114","author":"Y Echigoya","year":"2017","unstructured":"Echigoya Y, Nakamura A, Nagata T et al (2017) Effects of systemic multiexon skipping with peptide-conjugated morpholinos in the heart of a dog model of Duchenne muscular dystrophy. Proc Natl Acad Sci USA 114(16):4213\u20134218. https:\/\/doi.org\/10.1073\/pnas.1613203114","journal-title":"Proc Natl Acad Sci USA"},{"issue":"12","key":"5_CR10","doi-asserted-by":"publisher","first-page":"8174","DOI":"10.1093\/nar\/gku512","volume":"42","author":"T Shimo","year":"2014","unstructured":"Shimo T, Tachibana K, Saito K et al (2014) Design and evaluation of locked nucleic acid-based splice-switching oligonucleotides in vitro. Nucleic Acids Res 42(12):8174\u20138187. https:\/\/doi.org\/10.1093\/nar\/gku512","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"5_CR11","doi-asserted-by":"publisher","first-page":"29","DOI":"10.3233\/JND-150113","volume":"3","author":"M Rodrigues","year":"2016","unstructured":"Rodrigues M, Echigoya Y, Fukada S et al (2016) Current translational research and murine models for Duchenne muscular dystrophy. J Neuromuscul Dis 3(1):29\u201348","journal-title":"J Neuromuscul Dis"},{"issue":"9","key":"5_CR12","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1517\/14712598.2012.693469","volume":"12","author":"T Yokota","year":"2012","unstructured":"Yokota T, Duddy W, Echigoya Y et al (2012) Exon skipping for nonsense mutations in Duchenne muscular dystrophy: too many mutations, too few patients? Expert Opin Biol Ther 12(9):1141\u20131152. https:\/\/doi.org\/10.1517\/14712598.2012.693469","journal-title":"Expert Opin Biol Ther"},{"issue":"3","key":"5_CR13","doi-asserted-by":"publisher","first-page":"199","DOI":"10.3233\/JND-170233","volume":"4","author":"N Wein","year":"2017","unstructured":"Wein N, Vulin A, Findlay AR et al (2017) Efficient skipping of single exon duplications in DMD patient-derived cell lines using an antisense oligonucleotide approach. J Neuromuscul Dis 4(3):199\u2013207. https:\/\/doi.org\/10.3233\/JND-170233","journal-title":"J Neuromuscul Dis"},{"issue":"8","key":"5_CR14","first-page":"1314","volume":"7","author":"X Yu","year":"2015","unstructured":"Yu X, Bao B, Echigoya Y et al (2015) Dystrophin-deficient large animal models: translational research and exon skipping. Am J Transl Res 7(8):1314\u20131331","journal-title":"Am J Transl Res"},{"key":"5_CR15","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/978-1-4939-6817-6_17","volume":"1565","author":"R Maruyama","year":"2017","unstructured":"Maruyama R, Echigoya Y, Caluseriu O et al (2017) Systemic delivery of Morpholinos to skip multiple exons in a dog model of Duchenne muscular dystrophy. Methods Mol Biol 1565:201\u2013213. https:\/\/doi.org\/10.1007\/978-1-4939-6817-6_17","journal-title":"Methods Mol Biol"},{"issue":"3","key":"5_CR16","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1002\/humu.20918","volume":"30","author":"A Aartsma-Rus","year":"2009","unstructured":"Aartsma-Rus A, Fokkema I, Verschuuren J et al (2009) Theoretic applicability of antisense-mediated exon skipping for Duchenne muscular dystrophy mutations. Hum Mutat 30(3):293\u2013299. https:\/\/doi.org\/10.1002\/humu.20918","journal-title":"Hum Mutat"},{"key":"5_CR17","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/978-4-431-55678-7","volume-title":"Translational research in muscular dystrophy","author":"JJA Lee","year":"2016","unstructured":"Lee JJA, Yokota T (2016) Translational research in nucleic acid therapies for muscular dystrophies. In: Shin\u2019ichi Takeda YM-S et al (eds) Translational research in muscular dystrophy, 1st edn. Springer Japan, Tokyo, pp 87\u2013102. https:\/\/doi.org\/10.1007\/978-4-431-55678-7","edition":"1"},{"issue":"7367","key":"5_CR18","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1038\/nature10456","volume":"478","author":"M Taniguchi-Ikeda","year":"2011","unstructured":"Taniguchi-Ikeda M, Kobayashi K, Kanagawa M et al (2011) Pathogenic exon-trapping by SVA retrotransposon and rescue in Fukuyama muscular dystrophy. Nature 478(7367):127\u2013131. https:\/\/doi.org\/10.1038\/nature10456","journal-title":"Nature"},{"issue":"24","key":"5_CR19","doi-asserted-by":"publisher","first-page":"4914","DOI":"10.1093\/hmg\/ddt341","volume":"22","author":"Y Aoki","year":"2013","unstructured":"Aoki Y, Nagata T, Yokota T et al (2013) Highly efficient in vivo delivery of PMO into regenerating myotubes and rescue in laminin-alpha2 chain-null congenital muscular dystrophy mice. Hum Mol Genet 22(24):4914\u20134928. https:\/\/doi.org\/10.1093\/hmg\/ddt341","journal-title":"Hum Mol Genet"},{"issue":"2","key":"5_CR20","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1002\/humu.21160","volume":"31","author":"N Wein","year":"2010","unstructured":"Wein N, Avril A, Bartoli M et al (2010) Efficient bypass of mutations in Dysferlin deficient patient cells by antisense-induced exon skipping. Hum Mutat 31(2):136\u2013142. https:\/\/doi.org\/10.1002\/humu.21160","journal-title":"Hum Mutat"},{"issue":"9","key":"5_CR21","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1002\/acn3.96","volume":"1","author":"JA Dominov","year":"2014","unstructured":"Dominov JA, Uyan O, Sapp PC et al (2014) A novel dysferlin mutant pseudoexon bypassed with antisense oligonucleotides. Ann Clin Transl Neurol 1(9):703\u2013720. https:\/\/doi.org\/10.1002\/acn3.96","journal-title":"Ann Clin Transl Neurol"},{"key":"5_CR22","doi-asserted-by":"publisher","first-page":"533","DOI":"10.2147\/DDDT.S97635","volume":"11","author":"KR Lim","year":"2017","unstructured":"Lim KR, Maruyama R, Yokota T (2017) Eteplirsen in the treatment of Duchenne muscular dystrophy. Drug Des Devel Ther 11:533\u2013545. https:\/\/doi.org\/10.2147\/DDDT.S97635","journal-title":"Drug Des Devel Ther"},{"key":"5_CR23","doi-asserted-by":"publisher","unstructured":"Nguyen Q, Yokota T (2017) Immortalized muscle cell model to test the exon skipping efficacy for Duchenne muscular dystrophy. J Pers Med 7(4). https:\/\/doi.org\/10.3390\/jpm7040013","DOI":"10.3390\/jpm7040013"},{"issue":"6","key":"5_CR24","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1517\/14712598.2014.896335","volume":"14","author":"A Touznik","year":"2014","unstructured":"Touznik A, Lee JJ, Yokota T (2014) New developments in exon skipping and splice modulation therapies for neuromuscular diseases. Expert Opin Biol Ther 14(6):809\u2013819. https:\/\/doi.org\/10.1517\/14712598.2014.896335","journal-title":"Expert Opin Biol Ther"},{"issue":"3","key":"5_CR25","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1089\/oli.1.1997.7.187","volume":"7","author":"J Summerton","year":"1997","unstructured":"Summerton J, Weller D (1997) Morpholino antisense oligomers: design, preparation, and properties. Antisense Nucleic Acid Drug Dev 7(3):187\u2013195","journal-title":"Antisense Nucleic Acid Drug Dev"},{"issue":"1","key":"5_CR26","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1073\/pnas.0406700102","volume":"102","author":"QL Lu","year":"2005","unstructured":"Lu QL, Rabinowitz A, Chen YC et al (2005) Systemic delivery of antisense oligoribonucleotide restores dystrophin expression in body-wide skeletal muscles. Proc Natl Acad Sci USA 102(1):198\u2013203. https:\/\/doi.org\/10.1073\/pnas.0406700102","journal-title":"Proc Natl Acad Sci USA"},{"issue":"10","key":"5_CR27","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1212\/WNL.0000000000002445","volume":"86","author":"CA Chiriboga","year":"2016","unstructured":"Chiriboga CA, Swoboda KJ, Darras BT et al (2016) Results from a phase 1 study of nusinersen (ISIS-SMNRx) in children with spinal muscular atrophy. Neurology 86(10):890\u2013897. https:\/\/doi.org\/10.1212\/WNL.0000000000002445","journal-title":"Neurology"},{"issue":"1","key":"5_CR28","doi-asserted-by":"publisher","first-page":"3672","DOI":"10.1038\/s41598-017-03850-2","volume":"7","author":"A Touznik","year":"2017","unstructured":"Touznik A, Maruyama R, Hosoki K et al (2017) LNA\/DNA mixmer-based antisense oligonucleotides correct alternative splicing of the SMN2 gene and restore SMN protein expression in type 1 SMA fibroblasts. Sci Rep 7(1):3672. https:\/\/doi.org\/10.1038\/s41598-017-03850-2","journal-title":"Sci Rep"},{"key":"5_CR29","first-page":"143","volume-title":"Duchenne muscular dystrophy: methods and protocols","author":"T Shimo","year":"2017","unstructured":"Shimo T, Maruyama R, Yokota T (2017) Designing effective antisense oligonucleotides for exon skipping. In: Duchenne muscular dystrophy: methods and protocols. Springer, New York, pp 143\u2013155"},{"key":"5_CR30","doi-asserted-by":"publisher","first-page":"2561","DOI":"10.1016\/j.ymthe.2017.07.014","volume":"25","author":"Y Echigoya","year":"2017","unstructured":"Echigoya Y, Lim KRQ, Trieu N et al (2017) Quantitative antisense screening and optimization for exon 51 skipping in Duchenne muscular dystrophy. Mol Ther 25:2561. https:\/\/doi.org\/10.1016\/j.ymthe.2017.07.014","journal-title":"Mol Ther"},{"issue":"12","key":"5_CR31","doi-asserted-by":"publisher","first-page":"4030","DOI":"10.1093\/nar\/gkm358","volume":"35","author":"CJ Yang","year":"2007","unstructured":"Yang CJ, Wang L, Wu Y et al (2007) Synthesis and investigation of deoxyribonucleic acid\/locked nucleic acid chimeric molecular beacons. Nucleic Acids Res 35(12):4030\u20134041. https:\/\/doi.org\/10.1093\/nar\/gkm358","journal-title":"Nucleic Acids Res"},{"issue":"3","key":"5_CR32","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0120058","volume":"10","author":"Y Echigoya","year":"2015","unstructured":"Echigoya Y, Mouly V, Garcia L et al (2015) In silico screening based on predictive algorithms as a design tool for exon skipping oligonucleotides in Duchenne muscular dystrophy. PLoS One 10(3):e0120058. https:\/\/doi.org\/10.1371\/journal.pone.0120058","journal-title":"PLoS One"},{"issue":"3","key":"5_CR33","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1038\/mt.2008.205","volume":"17","author":"A Aartsma-Rus","year":"2009","unstructured":"Aartsma-Rus A, van Vliet L, Hirschi M et al (2009) Guidelines for antisense oligonucleotide design and insight into splice-modulating mechanisms. Mol Ther 17(3):548\u2013553. https:\/\/doi.org\/10.1038\/mt.2008.205","journal-title":"Mol Ther"},{"issue":"1","key":"5_CR34","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1001\/archneurol.2008.540","volume":"66","author":"T Yokota","year":"2009","unstructured":"Yokota T, Takeda S, Lu QL et al (2009) A renaissance for antisense oligonucleotide drugs in neurology: exon skipping breaks new ground. Arch Neurol 66(1):32\u201338","journal-title":"Arch Neurol"},{"issue":"8","key":"5_CR35","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0012239","volume":"5","author":"T Saito","year":"2010","unstructured":"Saito T, Nakamura A, Aoki Y et al (2010) Antisense PMO found in dystrophic dog model was effective in cells from exon 7-deleted DMD patient. PLoS One 5(8):e12239. https:\/\/doi.org\/10.1371\/journal.pone.0012239","journal-title":"PLoS One"},{"issue":"1","key":"5_CR36","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1089\/nat.2013.0451","volume":"24","author":"Y Echigoya","year":"2014","unstructured":"Echigoya Y, Yokota T (2014) Skipping multiple exons of dystrophin transcripts using cocktail antisense oligonucleotides. Nucleic Acid Ther 24(1):57\u201368. https:\/\/doi.org\/10.1089\/nat.2013.0451","journal-title":"Nucleic Acid Ther"},{"key":"5_CR37","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/402369","volume":"2013","author":"Y Aoki","year":"2013","unstructured":"Aoki Y, Yokota T, Wood MJ (2013) Development of multiexon skipping antisense oligonucleotide therapy for Duchenne muscular dystrophy. Biomed Res Int 2013:402369. https:\/\/doi.org\/10.1155\/2013\/402369","journal-title":"Biomed Res Int"},{"issue":"1","key":"5_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/biomedicines6010001","volume":"6","author":"T Aslesh","year":"2018","unstructured":"Aslesh T, Maruyama R, Yokota T (2018) Skipping multiple exons to treat DMD \u2013 promises and challenges. Biomedicines 6(1):1","journal-title":"Biomedicines"},{"key":"5_CR39","first-page":"S41","volume-title":"Molecular therapy","author":"Y Echigoya","year":"2014","unstructured":"Echigoya Y, Duddy W, Lee J et al (2014) Exons 45-55 skipping of human dystrophin transcripts using cocktail antisense oligonucleotides. In: Molecular therapy, vol 22. Nature Publishing Group, New York, pp S41\u2013S42"},{"issue":"4","key":"5_CR40","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1038\/jhg.2016.152","volume":"62","author":"A Nakamura","year":"2017","unstructured":"Nakamura A, Shiba N, Miyazaki D et al (2017) Comparison of the phenotypes of patients harboring in-frame deletions starting at exon 45 in the Duchenne muscular dystrophy gene indicates potential for the development of exon skipping therapy. J Hum Genet 62(4):459\u2013463. https:\/\/doi.org\/10.1038\/jhg.2016.152","journal-title":"J Hum Genet"},{"key":"5_CR41","doi-asserted-by":"publisher","DOI":"10.1038\/mtna.2014.76","volume":"4","author":"Y Echigoya","year":"2015","unstructured":"Echigoya Y, Aoki Y, Miskew B et al (2015) Long-term efficacy of systemic multiexon skipping targeting dystrophin exons 45-55 with a cocktail of vivo-morpholinos in mdx52 mice. Mol Ther Nucleic Acids 4:e225. https:\/\/doi.org\/10.1038\/mtna.2014.76","journal-title":"Mol Ther Nucleic Acids"},{"issue":"34","key":"5_CR42","doi-asserted-by":"publisher","first-page":"13763","DOI":"10.1073\/pnas.1204638109","volume":"109","author":"Y Aoki","year":"2012","unstructured":"Aoki Y, Yokota T, Nagata T et al (2012) Bodywide skipping of exons 45-55 in dystrophic mdx52 mice by systemic antisense delivery. Proc Natl Acad Sci USA 109(34):13763\u201313768. https:\/\/doi.org\/10.1073\/pnas.1204638109","journal-title":"Proc Natl Acad Sci USA"},{"issue":"4","key":"5_CR43","doi-asserted-by":"publisher","first-page":"13","DOI":"10.3390\/jpm7040013","volume":"7","author":"Q Nguyen","year":"2017","unstructured":"Nguyen Q, Yokota T (2017) Immortalized muscle cell model to test the exon skipping efficacy for Duchenne muscular dystrophy. J Pers Med 7(4):13","journal-title":"J Pers Med"},{"issue":"2","key":"5_CR44","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1002\/mus.20586","volume":"34","author":"A Aartsma-Rus","year":"2006","unstructured":"Aartsma-Rus A, Van Deutekom JC, Fokkema IF et al (2006) Entries in the Leiden Duchenne muscular dystrophy mutation database: an overview of mutation types and paradoxical cases that confirm the reading-frame rule. Muscle Nerve 34(2):135\u2013144","journal-title":"Muscle Nerve"},{"issue":"9","key":"5_CR45","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkp215","volume":"37","author":"FO Desmet","year":"2009","unstructured":"Desmet FO, Hamroun D, Lalande M et al (2009) Human splicing finder: an online bioinformatics tool to predict splicing signals. Nucleic Acids Res 37(9):e67. https:\/\/doi.org\/10.1093\/nar\/gkp215","journal-title":"Nucleic Acids Res"},{"issue":"13","key":"5_CR46","doi-asserted-by":"publisher","first-page":"3406","DOI":"10.1093\/nar\/gkg595","volume":"31","author":"M Zuker","year":"2003","unstructured":"Zuker M (2003) Mfold web server for nucleic acid folding and hybridization prediction. Nucleic Acids Res 31(13):3406\u20133415","journal-title":"Nucleic Acids Res"},{"key":"5_CR47","doi-asserted-by":"publisher","first-page":"W43","DOI":"10.1093\/nar\/gkm234","volume":"35","author":"WA Kibbe","year":"2007","unstructured":"Kibbe WA (2007) OligoCalc: an online oligonucleotide properties calculator. Nucleic Acids Res 35:W43\u2013W46. https:\/\/doi.org\/10.1093\/nar\/gkm234","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"5_CR48","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1093\/nar\/30.1.38","volume":"30","author":"T Hubbard","year":"2002","unstructured":"Hubbard T, Barker D, Birney E et al (2002) The Ensembl genome database project. Nucleic Acids Res 30(1):38\u201341","journal-title":"Nucleic Acids Res"},{"issue":"D1","key":"5_CR49","doi-asserted-by":"publisher","first-page":"D717","DOI":"10.1093\/nar\/gkv1275","volume":"44","author":"ML Speir","year":"2016","unstructured":"Speir ML, Zweig AS, Rosenbloom KR et al (2016) The UCSC genome browser database: 2016 update. Nucleic Acids Res 44(D1):D717\u2013D725. https:\/\/doi.org\/10.1093\/nar\/gkv1275","journal-title":"Nucleic Acids Res"},{"issue":"6","key":"5_CR50","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1517\/14712598.7.6.831","volume":"7","author":"T Yokota","year":"2007","unstructured":"Yokota T, Pistilli E, Duddy W et al (2007) Potential of oligonucleotide-mediated exon-skipping therapy for Duchenne muscular dystrophy. Expert Opin Biol Ther 7(6):831\u2013842. https:\/\/doi.org\/10.1517\/14712598.7.6.831","journal-title":"Expert Opin Biol Ther"},{"issue":"4","key":"5_CR51","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1038\/jhg.2016.152","volume":"62","author":"A Nakamura","year":"2016","unstructured":"Nakamura A, Shiba N, Miyazaki D et al (2016) Comparison of the phenotypes of patients harboring in-frame deletions starting at exon 45 in the Duchenne muscular dystrophy gene indicates potential for the development of exon skipping therapy. J Hum Genet 62(4):459\u2013463","journal-title":"J Hum Genet"},{"issue":"3","key":"5_CR52","first-page":"179","volume":"26","author":"T Yokota","year":"2007","unstructured":"Yokota T, Duddy W, Partridge T (2007) Optimizing exon skipping therapies for DMD. Acta Myol 26(3):179\u2013184","journal-title":"Acta Myol"},{"issue":"13","key":"5_CR53","doi-asserted-by":"publisher","first-page":"3568","DOI":"10.1093\/nar\/gkg616","volume":"31","author":"L Cartegni","year":"2003","unstructured":"Cartegni L, Wang J, Zhu Z et al (2003) ESEfinder: a web resource to identify exonic splicing enhancers. Nucleic Acids Res 31(13):3568\u20133571","journal-title":"Nucleic Acids Res"},{"key":"5_CR54","doi-asserted-by":"publisher","first-page":"W187","DOI":"10.1093\/nar\/gkh393","volume":"32","author":"WG Fairbrother","year":"2004","unstructured":"Fairbrother WG, Yeo GW, Yeh R et al (2004) RESCUE-ESE identifies candidate exonic splicing enhancers in vertebrate exons. Nucleic Acids Res 32:W187\u2013W190. https:\/\/doi.org\/10.1093\/nar\/gkh393","journal-title":"Nucleic Acids Res"},{"key":"5_CR55","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/978-1-61737-982-6_20","volume":"709","author":"T Yokota","year":"2011","unstructured":"Yokota T, Hoffman E, Takeda S (2011) Antisense oligo-mediated multiple exon skipping in a dog model of Duchenne muscular dystrophy. Methods Mol Biol 709:299\u2013312. https:\/\/doi.org\/10.1007\/978-1-61737-982-6_20","journal-title":"Methods Mol Biol"},{"issue":"1","key":"5_CR56","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.nmd.2013.09.004","volume":"24","author":"KM Flanigan","year":"2014","unstructured":"Flanigan KM, Voit T, Rosales XQ et al (2014) Pharmacokinetics and safety of single doses of drisapersen in non-ambulant subjects with Duchenne muscular dystrophy: results of a double-blind randomized clinical trial. Neuromuscul Disord 24(1):16\u201324. https:\/\/doi.org\/10.1016\/j.nmd.2013.09.004","journal-title":"Neuromuscul Disord"},{"issue":"10","key":"5_CR57","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1016\/S1474-4422(14)70195-4","volume":"13","author":"T Voit","year":"2014","unstructured":"Voit T, Topaloglu H, Straub V et al (2014) Safety and efficacy of drisapersen for the treatment of Duchenne muscular dystrophy (DEMAND II): an exploratory, randomised, placebo-controlled phase 2 study. Lancet Neurol 13(10):987\u2013996. https:\/\/doi.org\/10.1016\/S1474-4422(14)70195-4","journal-title":"Lancet Neurol"},{"issue":"5","key":"5_CR58","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1002\/ana.23982","volume":"74","author":"JR Mendell","year":"2013","unstructured":"Mendell JR, Rodino-Klapac LR, Sahenk Z et al (2013) Eteplirsen for the treatment of Duchenne muscular dystrophy. Ann Neurol 74(5):637\u2013647. https:\/\/doi.org\/10.1002\/ana.23982","journal-title":"Ann Neurol"},{"issue":"3","key":"5_CR59","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/nm.3765","volume":"21","author":"A Goyenvalle","year":"2015","unstructured":"Goyenvalle A, Griffith G, Babbs A et al (2015) Functional correction in mouse models of muscular dystrophy using exon-skipping tricyclo-DNA oligomers. Nat Med 21(3):270\u2013275. https:\/\/doi.org\/10.1038\/nm.3765","journal-title":"Nat Med"},{"issue":"1","key":"5_CR60","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1038\/sj.mt.6300006","volume":"15","author":"PL Harding","year":"2007","unstructured":"Harding PL, Fall AM, Honeyman K et al (2007) The influence of antisense oligonucleotide length on dystrophin exon skipping. Mol Ther 15(1):157\u2013166. https:\/\/doi.org\/10.1038\/sj.mt.6300006","journal-title":"Mol Ther"},{"issue":"Suppl 1","key":"5_CR61","doi-asserted-by":"publisher","first-page":"S33","DOI":"10.1186\/1471-2105-10-S1-S33","volume":"10","author":"CY Chan","year":"2009","unstructured":"Chan CY, Carmack CS, Long DD et al (2009) A structural interpretation of the effect of GC-content on efficiency of RNA interference. BMC Bioinformatics 10(Suppl 1):S33. https:\/\/doi.org\/10.1186\/1471-2105-10-S1-S33","journal-title":"BMC Bioinformatics"},{"issue":"18","key":"5_CR62","doi-asserted-by":"publisher","first-page":"8638","DOI":"10.1093\/nar\/gkv857","volume":"43","author":"PJ Kamola","year":"2015","unstructured":"Kamola PJ, Kitson JD, Turner G et al (2015) In silico and in vitro evaluation of exonic and intronic off-target effects form a critical element of therapeutic ASO gapmer optimization. Nucleic Acids Res 43(18):8638\u20138650. https:\/\/doi.org\/10.1093\/nar\/gkv857","journal-title":"Nucleic Acids Res"},{"key":"5_CR63","doi-asserted-by":"publisher","first-page":"30377","DOI":"10.1038\/srep30377","volume":"6","author":"T Kasuya","year":"2016","unstructured":"Kasuya T, Hori S, Watanabe A et al (2016) Ribonuclease H1-dependent hepatotoxicity caused by locked nucleic acid-modified gapmer antisense oligonucleotides. Sci Rep 6:30377. https:\/\/doi.org\/10.1038\/srep30377","journal-title":"Sci Rep"},{"issue":"13","key":"5_CR64","doi-asserted-by":"publisher","first-page":"3758","DOI":"10.1093\/nar\/gkg580","volume":"31","author":"N Tolstrup","year":"2003","unstructured":"Tolstrup N, Nielsen PS, Kolberg JG et al (2003) OligoDesign: optimal design of LNA (locked nucleic acid) oligonucleotide capture probes for gene expression profiling. Nucleic Acids Res 31(13):3758\u20133762","journal-title":"Nucleic Acids Res"},{"issue":"7","key":"5_CR65","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1089\/hum.2013.234","volume":"25","author":"P Disterer","year":"2014","unstructured":"Disterer P, Kryczka A, Liu Y et al (2014) Development of therapeutic splice-switching oligonucleotides. Hum Gene Ther 25(7):587\u2013598. https:\/\/doi.org\/10.1089\/hum.2013.234","journal-title":"Hum Gene Ther"},{"issue":"11","key":"5_CR66","doi-asserted-by":"publisher","first-page":"2979","DOI":"10.1093\/nar\/19.11.2979","volume":"19","author":"L Kibler-Herzog","year":"1991","unstructured":"Kibler-Herzog L, Zon G, Uznanski B et al (1991) Duplex stabilities of phosphorothioate, methylphosphonate, and RNA analogs of two DNA 14-mers. Nucleic Acids Res 19(11):2979\u20132986","journal-title":"Nucleic Acids Res"},{"key":"5_CR67","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1093\/nass\/48.1.297","volume":"48","author":"M Takagi","year":"2004","unstructured":"Takagi M, Yagi M, Ishibashi K et al (2004) Design of 2\u2032-O-me RNA\/ENA chimera oligonucleotides to induce exon skipping in dystrophin pre-mRNA. Nucleic Acids Symp Ser (Oxf) 48:297\u2013298. https:\/\/doi.org\/10.1093\/nass\/48.1.297","journal-title":"Nucleic Acids Symp Ser (Oxf)"},{"key":"5_CR68","doi-asserted-by":"publisher","unstructured":"Miskew Nichols B, Aoki Y, Kuraoka M et al (2016) Multi-exon skipping using cocktail antisense oligonucleotides in the canine X-linked muscular dystrophy. J Vis Exp 111. https:\/\/doi.org\/10.3791\/53776","DOI":"10.3791\/53776"},{"issue":"6","key":"5_CR69","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1002\/ana.21627","volume":"65","author":"T Yokota","year":"2009","unstructured":"Yokota T, Lu QL, Partridge T et al (2009) Efficacy of systemic morpholino exon-skipping in Duchenne dystrophy dogs. Ann Neurol 65(6):667\u2013676. https:\/\/doi.org\/10.1002\/ana.21627","journal-title":"Ann Neurol"},{"key":"5_CR70","volume-title":"Morpholino Oligos","author":"R Maruyama","year":"2016","unstructured":"Maruyama R, Aoki Y, Echigoya Y et al (2016) Morpholino-mediated multi-exon skipping in dystrophic dogs. In: Moulton H, Moulton J (eds) Morpholino Oligos. Humana Press, New York"},{"issue":"5","key":"5_CR71","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1089\/nat.2012.0368","volume":"22","author":"T Yokota","year":"2012","unstructured":"Yokota T, Nakamura A, Nagata T et al (2012) Extensive and prolonged restoration of dystrophin expression with vivo-morpholino-mediated multiple exon skipping in dystrophic dogs. Nucleic Acid Ther 22(5):306\u2013315. https:\/\/doi.org\/10.1089\/nat.2012.0368","journal-title":"Nucleic Acid Ther"},{"key":"5_CR72","first-page":"18","volume-title":"Molecular therapy","author":"R Maruyama","year":"2017","unstructured":"Maruyama R, Echigoya Y, Nakamura A et al (2017) Systemic injections of peptide-conjugated Morpholinos improve cardiac symptoms of a dog model of Duchenne muscular dystrophy. In: Molecular therapy. Cell Press, Cambridge, p 18"},{"issue":"2","key":"5_CR73","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1002\/humu.21160","volume":"31","author":"N Wein","year":"2010","unstructured":"Wein N, Avril A, Bartoli M et al (2010) Efficient bypass of mutations in dysferlin deficient patient cells by antisense-induced exon skipping. Hum Mutat 31(2):136\u2013142. https:\/\/doi.org\/10.1002\/humu.21160","journal-title":"Hum Mutat"},{"issue":"3","key":"5_CR74","doi-asserted-by":"publisher","first-page":"e139","DOI":"10.1016\/j.ddstr.2013.06.002","volume":"10","author":"L Spraggon","year":"2013","unstructured":"Spraggon L, Cartegni L (2013) Antisense modulation of RNA processing as a therapeutic approach in cancer therapy. Drug Discov Today Ther Strateg 10(3):e139\u2013e148. https:\/\/doi.org\/10.1016\/j.ddstr.2013.06.002","journal-title":"Drug Discov Today Ther Strateg"},{"issue":"43","key":"5_CR75","doi-asserted-by":"publisher","first-page":"17779","DOI":"10.1073\/pnas.1108482108","volume":"108","author":"F Zammarchi","year":"2011","unstructured":"Zammarchi F, de Stanchina E, Bournazou E et al (2011) Antitumorigenic potential of STAT3 alternative splicing modulation. Proc Natl Acad Sci USA 108(43):17779\u201317784. https:\/\/doi.org\/10.1073\/pnas.1108482108","journal-title":"Proc Natl Acad Sci USA"},{"issue":"3","key":"5_CR76","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1038\/nm.3106","volume":"19","author":"JJ Lentz","year":"2013","unstructured":"Lentz JJ, Jodelka FM, Hinrich AJ et al (2013) Rescue of hearing and vestibular function by antisense oligonucleotides in a mouse model of human deafness. Nat Med 19(3):345\u2013350. https:\/\/doi.org\/10.1038\/nm.3106","journal-title":"Nat Med"},{"issue":"6","key":"5_CR77","doi-asserted-by":"publisher","first-page":"3318","DOI":"10.1093\/nar\/gkv163","volume":"43","author":"A Wojtkowiak-Szlachcic","year":"2015","unstructured":"Wojtkowiak-Szlachcic A, Taylor K, Stepniak-Konieczna E et al (2015) Short antisense-locked nucleic acids (all-LNAs) correct alternative splicing abnormalities in myotonic dystrophy. Nucleic Acids Res 43(6):3318\u20133331. https:\/\/doi.org\/10.1093\/nar\/gkv163","journal-title":"Nucleic Acids Res"},{"issue":"11","key":"5_CR78","doi-asserted-by":"publisher","first-page":"4186","DOI":"10.1172\/JCI82768","volume":"125","author":"QQ Gao","year":"2015","unstructured":"Gao QQ, Wyatt E, Goldstein JA et al (2015) Reengineering a transmembrane protein to treat muscular dystrophy using exon skipping. J Clin Invest 125(11):4186\u20134195. https:\/\/doi.org\/10.1172\/JCI82768","journal-title":"J Clin Invest"},{"issue":"7","key":"5_CR79","doi-asserted-by":"publisher","first-page":"4114","DOI":"10.1073\/pnas.0633863100","volume":"100","author":"LA Skordis","year":"2003","unstructured":"Skordis LA, Dunckley MG, Yue B et al (2003) Bifunctional antisense oligonucleotides provide a trans-acting splicing enhancer that stimulates SMN2 gene expression in patient fibroblasts. Proc Natl Acad Sci USA 100(7):4114\u20134119. https:\/\/doi.org\/10.1073\/pnas.0633863100","journal-title":"Proc Natl Acad Sci USA"},{"issue":"6","key":"5_CR80","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1016\/j.ymthe.2005.08.022","volume":"12","author":"C Madocsai","year":"2005","unstructured":"Madocsai C, Lim SR, Geib T et al (2005) Correction of SMN2 pre-mRNA splicing by antisense U7 small nuclear RNAs. Mol Ther 12(6):1013\u20131022. https:\/\/doi.org\/10.1016\/j.ymthe.2005.08.022","journal-title":"Mol Ther"},{"issue":"4","key":"5_CR81","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.0050073","volume":"5","author":"Y Hua","year":"2007","unstructured":"Hua Y, Vickers TA, Baker BF et al (2007) Enhancement of SMN2 exon 7 inclusion by antisense oligonucleotides targeting the exon. PLoS Biol 5(4):e73","journal-title":"PLoS Biol"},{"issue":"9","key":"5_CR82","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1093\/hmg\/ddp076","volume":"18","author":"TD Baughan","year":"2009","unstructured":"Baughan TD, Dickson A, Osman EY et al (2009) Delivery of bifunctional RNAs that target an intronic repressor and increase SMN levels in an animal model of spinal muscular atrophy. Hum Mol Genet 18(9):1600\u20131611. https:\/\/doi.org\/10.1093\/hmg\/ddp076","journal-title":"Hum Mol Genet"},{"issue":"24","key":"5_CR83","doi-asserted-by":"publisher","first-page":"7633","DOI":"10.1523\/JNEUROSCI.0950-09.2009","volume":"29","author":"JH Williams","year":"2009","unstructured":"Williams JH, Schray RC, Patterson CA et al (2009) Oligonucleotide-mediated survival of motor neuron protein expression in CNS improves phenotype in a mouse model of spinal muscular atrophy. J Neurosci 29(24):7633\u20137638. https:\/\/doi.org\/10.1523\/JNEUROSCI.0950-09.2009","journal-title":"J Neurosci"},{"issue":"15","key":"5_CR84","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1101\/gad.1941310","volume":"24","author":"Y Hua","year":"2010","unstructured":"Hua Y, Sahashi K, Hung G et al (2010) Antisense correction of SMN2 splicing in the CNS rescues necrosis in a type III SMA mouse model. Genes Dev 24(15):1634\u20131644. https:\/\/doi.org\/10.1101\/gad.1941310","journal-title":"Genes Dev"},{"issue":"72","key":"5_CR85","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3001777","volume":"3","author":"MA Passini","year":"2011","unstructured":"Passini MA, Bu J, Richards AM et al (2011) Antisense oligonucleotides delivered to the mouse CNS ameliorate symptoms of severe spinal muscular atrophy. Sci Transl Med 3(72):72ra18. https:\/\/doi.org\/10.1126\/scitranslmed.3001777","journal-title":"Sci Transl Med"},{"issue":"4","key":"5_CR86","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0062114","volume":"8","author":"C Mitrpant","year":"2013","unstructured":"Mitrpant C, Porensky P, Zhou H et al (2013) Improved antisense oligonucleotide design to suppress aberrant SMN2 gene transcript processing: towards a treatment for spinal muscular atrophy. PLoS One 8(4):e62114. https:\/\/doi.org\/10.1371\/journal.pone.0062114","journal-title":"PLoS One"}],"container-title":["Methods in Molecular Biology","Exon Skipping and Inclusion Therapies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-1-0716-4730-1_5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T12:06:11Z","timestamp":1780747571000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-1-0716-4730-1_5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"ISBN":["9781071647295","9781071647301"],"references-count":86,"URL":"https:\/\/doi.org\/10.1007\/978-1-0716-4730-1_5","relation":{},"ISSN":["1064-3745","1940-6029"],"issn-type":[{"value":"1064-3745","type":"print"},{"value":"1940-6029","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025]]},"assertion":[{"value":"29 July 2025","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}